Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 16/20 | 0.68 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.61 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14844531 | 0.83 | NPBWR1 (0.84) | NPBWR1MCHR1 | |
| SCHEMBL28018215 | 0.82 | NPBWR1 (0.58) | NPBWR1MCHR1CMA1 | |
| SCHEMBL34471559 | 0.82 | NPBWR1 (0.58) | NPBWR1MCHR1CMA1GSK3AGSK3B | |
| SCHEMBL13724241 | 0.82 | NPBWR1 (0.56) | NPBWR1MCHR1CMA1GSK3AGSK3B | |
| SCHEMBL2551062 | 0.82 | NPBWR1 (0.77) | NPBWR1MCHR1 | |
| SCHEMBL29730000 | 0.81 | NPBWR1 (0.60) | NPBWR1MCHR1CMA1GSK3AGSK3B | |
| SCHEMBL29841887 | 0.81 | NPBWR1 (0.56) | NPBWR1MCHR1CMA1GSK3AGSK3B | |
| SCHEMBL24687649 | 0.81 | NPBWR1 (0.75) | NPBWR1MCHR1 | |
| SCHEMBL27884414 | 0.80 | NPBWR1 (0.54) | NPBWR1MCHR1CMA1GSK3AGSK3B | |
| SCHEMBL27252464 | 0.79 | NPBWR1 (0.54) | NPBWR1MCHR1CMA1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026086928-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2026-04-30 | — | — | WO | disclosed |
| CN-112689528-B | Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use | 基因泰克公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3849663-B1 | PYRIMIDINYL-HETEROARYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20220048888-A1 | PYRIMIDINYL-HETEROARYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-02-17 | — | — | US | disclosed |
| CN-112689528-A | Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use | 基因泰克公司 | 2021-04-20 | — | — | CN | disclosed |
| CN-1088578-A | 3 (2H)-pyridazinone derivatives and preparation method thereof | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1994-06-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048888-A1 | PYRIMIDINYL-HETEROARYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF USE | XBP1, HSPA5, HSP90B1 | NPBWR1 2719/4885MCHR1 4572/4885CMA1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.